Stoke Therapeutics News and Resources

Biogen Inc. and Stoke Therapeutics, Inc. have entered into a collaboration to develop and commercialize zorevunersen, an investigational treatment for Dravet syndrome, in all territories outside the U.S., Canada, and Mexico. The agreement grants Biogen exclusive commercialization rights outside these regions,